Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.36 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077750 | 0.85 | HTR6 (0.42) | HTR6P2RX7IL1BHTR1AHTR1B | |
| SCHEMBL4812247 | 0.74 | HTR6 (0.40) | HTR6GRIN2BKCNH2GRIN1KMT2A | |
| SCHEMBL4819132 | 0.73 | REN (0.39) | HTR6 | |
| SCHEMBL4817289 | 0.72 | GAA (0.38) | HTR6GRIN2BGRIN1 | |
| SCHEMBL4069815 | 0.72 | HTR6 (0.45) | HTR6PAK1P2RX7IL1BHTR2C | |
| SCHEMBL28753571 | 0.71 | MAPT (0.35) | HTR6P2RX7IL1BHTR1ACYP2D6 | |
| SCHEMBL4074804 | 0.70 | HTR6 (0.45) | HTR6 | |
| SCHEMBL4075071 | 0.70 | HTR6 (0.56) | HTR6 | |
| SCHEMBL4819209 | 0.69 | HTR6 (0.50) | HTR6 | |
| SCHEMBL4073065 | 0.69 | HTR6 (0.47) | HTR6HTR1ACYP2D6DRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057039-B2 | 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-06-06 | — | — | US | claimed |
| EP-1551840-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040023970-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | claimed |
| WO-2004009600-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-01-29 | — | — | WO | claimed |
| US-20080306106-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-7411064-B2 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060142330-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-06-29 | — | — | US | disclosed |
| US-7057039-B2 | 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040023970-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306106-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR2C | HTR6 1/4885PAK1 2339/4885P2RX7 189/4885 |
| US-20040023970-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR5A | HTR6 1/4885PAK1 2126/4885P2RX7 196/4885 |
| US-20060142330-A1 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885PAK1 2339/4885P2RX7 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.